Caprock Group LLC Invests $7.29 Million in Novo Nordisk A/S (NYSE:NVO)

Caprock Group LLC purchased a new stake in Novo Nordisk A/S (NYSE:NVO) during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 61,252 shares of the company’s stock, valued at approximately $7,293,000.

A number of other institutional investors also recently made changes to their positions in NVO. Pathstone Holdings LLC lifted its holdings in Novo Nordisk A/S by 0.3% during the 3rd quarter. Pathstone Holdings LLC now owns 290,229 shares of the company’s stock worth $34,558,000 after purchasing an additional 734 shares during the last quarter. Aviance Capital Partners LLC lifted its holdings in shares of Novo Nordisk A/S by 4.7% during the third quarter. Aviance Capital Partners LLC now owns 17,091 shares of the company’s stock worth $2,035,000 after buying an additional 770 shares in the last quarter. Baron Wealth Management LLC boosted its position in shares of Novo Nordisk A/S by 18.8% in the third quarter. Baron Wealth Management LLC now owns 3,224 shares of the company’s stock valued at $384,000 after acquiring an additional 510 shares during the period. Nixon Peabody Trust Co. bought a new position in Novo Nordisk A/S during the third quarter worth about $247,000. Finally, Semus Wealth Partners LLC acquired a new stake in Novo Nordisk A/S in the 3rd quarter worth about $420,000. Institutional investors own 11.54% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the company. BMO Capital Markets cut their price target on Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating for the company in a research note on Thursday, October 17th. StockNews.com upgraded shares of Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research note on Friday, November 1st. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $144.50.

Novo Nordisk A/S Trading Down 1.9 %

NYSE NVO opened at $99.82 on Tuesday. The company has a market cap of $447.95 billion, a price-to-earnings ratio of 32.30, a price-to-earnings-growth ratio of 1.31 and a beta of 0.42. Novo Nordisk A/S has a twelve month low of $94.73 and a twelve month high of $148.15. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.43. The business’s fifty day moving average is $117.94 and its 200 day moving average is $129.42.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.